. 2019 Nov 17;9(1):215–224. doi: 10.1002/cam4.2704

Table 3.

Multivariable Cox proportional hazard ratio estimates adjusting for baseline composite ESAS symptom burden

	Model 1^a	Model 2^a	Model 3^a	Model 4^a
	HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)
TSDS
High vs low	1.50 (1.35, 1.66)^*	—	—	—
PHS
High vs low	—	1.59 (1.43, 1.77)^*	—	1.58 (1.41, 1.78)^*
PSS
High vs low	—	—	1.20 (1.08, 1.32)^*	1.02 (0.91, 1.14)
Treatment
FOLFIRINOX vs gemcitabine	0.75 (0.67, 0.83)^*	0.75 (0.67, 0.83)^*	0.73 (0.66, 0.82)^*	0.75 (0.67, 0.83)^*
Gemcitabine‐nab paclitaxel vs gemcitabine	1.24 (1.02, 1.51)^*	1.23 (1.01, 1.50)^*	1.24 (1.01, 1.51)^*	1.23 (1.01, 1.50)^*

Abbreviations: CI, confidence interval; TSDS, baseline total symptom distress score; PHS, baseline physical symptom scores; PSS, baseline psychological symptom scores.

Model also adjusted for age at first‐line treatment, gender, rurality, neighborhood income quintile, Charlson‐Deyo score, previous adjuvant gemcitabine, previous pancreatic resection, and previous radiation.

P < .05.